H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on ObsEva SA (OBSV) today and set a price target of $44. The company’s shares closed on Friday at $12.63.
Selvaraju noted:
“Valuation methodology, risks and uncertainties. Our risk-adjusted net present value (rNPV) approach ascribes $1.95B to linzagolix (formerly to nolasiban. We utilize an 85% probability of approval for linzagolix and 75% for nolasiban. The current total valuation of $2.35B translates to $44.00 per share, assuming roughly 54M fully-diluted shares outstanding as of end-1Q 2020.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -3.0% and a 29.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on ObsEva SA is a Strong Buy with an average price target of $33.60.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.35 and a one-year low of $10.23. Currently, ObsEva SA has an average volume of 49.04K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ObsEva SA engages in the development of therapeutic treatments for woman’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.
